Hamdan Medical Journal (previously the Journal of Medical Sciences)

Table of Contents  

Surgical Trends in the Treatment of Parkinson’s Disease and Their Outcome

Sofia Ahmed, Muhammad Ali Sheraz, Iqbal Ahmad
Published in : Journal of Medical Sciences ; Vol 3, No 3 (2010)
DOI : 10.2174/1996327001003030142

Abstract


Parkinson’s disease (PD) is one of the most common neurodegenerative disorders featuring the cardinal symptoms of resting tremors, postural instability, rigidity, bradykinesia and akinesia treated with a range of medicinal agents. The traditional drug therapy usually involves levodopa, the most potent drug for controlling PD symptoms, along with catechol-O-methyl-transferase inhibitors (COMTI), dopamine agonists and nondopaminergic drugs. For the last few years the treatment includes surgical techniques specially deep-brain stimulation, subthalamotomy, pallidotomy, thalamotomy, etc. The lay literature and mass media descriptions of surgery for PD often give patients and their families the impression that today’s surgical procedures offer miraculous results to all patients undergoing this treatment. However, it is an important fact that these new treatments are not necessarily better than the established conventional drug therapy and that the treatment options must be selected according to the need of individual patient.

Keywords


Parkinson’s disease; lesional or ablative procedures; deep brain

View article in  :   PDF    

References


Lilienfeld DE, Perl DP. Projected neurodegenerative disease mortality in the United States, 1990-2040. Neuroepidemiology 1993; 12: 219-28.

Schapira AHV, Hartmann A, Agid Y, Eds. Parkinsonian Disorders in Clinical Practice, Blackwell Publishing Limited 2009.

Tugwell C. Parkinson’s Disease in Focus, Pharmaceutical Press 2008.

Gregory MC, Strong MB. Diseases: manifestations and pathophysiology. In: Hendrickson R, Ed. Remington The Science and Practice of Pharmacy, 21st ed., Lippincott Williams and Wilkins, Philadelphia 2006; p. 1117.

Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. In: Brunton LL, Lazo JS, Parker KL, Eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics, 11th ed., McGraw-Hill Companies 2006; Chap. 20.

Chen JJ, Nelson MV, Swope DM. Parkinson’s Disease. In: DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM, Eds. Pharmacotherapy A Pathophysiologic Approach, 7th ed. McGraw-Hill Companies 2008; Chap. 61.

Sweetman, SC, Ed. Martindale: The Complete Drug Reference, 35th ed. Pharmaceutical Press, London; Electronic version 2007.

Lang AE, Lozano AM. Parkinson's disease. First of two parts. New Engl J Med 1998; 339: 1044-53.

Fukunaga H, Kasai T, Yoshidome H. Clinical findings, status of care, comprehensive quality of life, daily life therapy and treatment at home in patients with Parkinson’s disease. Eur Neurol 1997; 38: 64-9.

Aminoff MJ. Pharmacologic management of Parkinsonism and other movement disorders. In: Katzung BG, Masters SB, Trevor AJ, Eds. Basic and Clinical Pharmacology, 11th ed., McGraw-Hill Companies 2009; Chap. 28.

Thurman DJ, Stevens JA, Rao JK. Quality standards subcommittee of the American academy of neurology. Practice parameter: Assessing patients in a neurology practice for risk of falls (an evidence-based review): report of the quality standards

subcommittee of the American academy of neurology. Neurology 2008; 70: 473-9.

MacDonald BK, Cockerell OC, Sander JWAS, Shorvon SD. The incidence and life time prevalence of neurological disorders in a prospective community-based study in the UK. Brain 2000; 123: 665-76.

Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976–1990. Neurology 1999; 52: 1214- 20.

Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson's disease: variation by age, gender, and race / ethnicity. Am J Epidemiol 2003; 157:1015-22.

Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord 2003; 18: 19-31.

Krack P, Limousin P, Benabid AL, Pollak P. Chronic stimulation of subthalamic nucleus improves levodopainduced dyskinesias in Parkinson’s disease. Lancet 1997; 350: 1676.

Laitinen LV, Bergenheim AT, Hariz MI. Leksell’s posteroventral pallidotomy in the treatment of Parkinson’s disease. J Neurosurg 1992; 76: 53-61.

Lozano AM, Lang AE, Galvez-Jimenez N, Miyasaki J, Duff J, Hutchinson WD, et al. Effect of GPi pallidotomy on motor function in Parkinson’s disease. Lancet 1995; 346: 1383-7.

Danish SF, Burnett MG, Ong JG, Sonnad SS, Maloney- Wilensky E, Stein SC. Prophylaxis for deep venous thrombosis in craniotomy patients: a decision analysis. Neurosurgery 2005; 56: 1286-92.

Vitek JL, Bakay RA, Hashimoto T, Kaneoke Y, Mewes K, Zhang JY, et al. Microelectrode-guided pallidotomy: technical approach and its application in medically intractable Parkinson’s disease. J Neurosurg 1998; 88: 1027- 43.

Clark CRA. Neurological disease. In: Kumar P, Clark M, Eds. Clinical Medicine, 7th ed., Elsevier 2009; Chap. 21.

Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease, a clinico-pathological study of 100 cases. J Neurol Neurosurg Psych 1992; 55: 181-4.

Shimohama S. Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models. Biol Pharm Bull 2009; 32: 332-6.

LeWitt PA, Berchou RC. Parkinson disease. In: Linn WD, Wofford MR, O’Keefe ME, Posey LM, Eds. Pharmacotherapy in Primary Care: McGraw-Hill Companies 2009; Chap. 17.

Wagner ML. Parkinson’s disease. In: Chisholm-burns MA, Wells BG, Schwinghammer TL, Malone PM, Kolesar JM, Rotschafer JC, Dipiro JT, Eds. Pharmacotherapy Principles and Practice: McGraw-Hill Companies 2008; Chap. 29.

Mizuno Y, Hattori N, Kubo S, Sato S, Nishioka K, Hatano T, et al. Progress in the pathogenesis and genetics of Parkinson's disease. Philos Trans R Soc Lond B Biol Sci 2008; 363: 2215-27.

Levy G, Schupf N, Tang MX, Cote LJ, Louis ED, Mejia H, et al. Combined effect of age and severity on the risk of dementia in Parkinson’s disease. Ann Neurol 2002; 51:722- 9.

Halvorsen phi, Tysnes OB. Dementia in Parkinson's disease. Tidsskr Nor Laegeforen 2007; 127: 2517-20.

Caixeta L, Vieira RT. Dementia in Parkinson's disease. Rev Bras Psiquiatr 2008; 30: 375-83.

Aarsland D, Tandberg E, Larsen JP, Cummings JL. Frequency of dementia in Parkinson disease. Arch Neurol 1996; 53: 538-42.

Cardoso EF, Maia FM, Fregni F, Myczkowski ML, Melo LM, Sato JR, et al. Depression in Parkinson's disease: Convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus. Neuroimage 2009; 47: 467-472.

Cardoso EF, Maia FM, Fregni F, Myczkowski ML, Melo LM, Sato JR, et al. Depressive symptoms in Parkinson disease correlate with impaired global and specific cognitive performance. J Geriatr Psychiatry Neurol 2009; 22: 223-7.

Emre M. Dementia associated with Parkinson’s disease. Lancet Neurol 2003; 2: 229-37.

Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson’s disease: diagnosis and management. Lancet Neurol 2006; 5: 235-45.

Monderer R, Thorpy M. Sleep disorders and daytime sleepiness in Parkinson's disease. Curr Neurol Neurosci Rep 2009; 9:173-80.

Stavitsky K, McNamara P, Durso R, Harris E, Auerbach S, Cronin-Golomb A. Hallucinations, dreaming, and frequent dozing in Parkinson disease: impact of right-hemisphere neural networks. Cogn Behav Neurol 2008; 21: 143-9.

Kulakowska A, Kapica-Topczewska K, Halicka D, Drozdowski W. Sleep disturbances and their effect on the sustained attention in patients with Parkinson's disease. Pol Merkur Lekarski 2008; 24: 109-12.

Arnulf I, Leu S, Oudiette D. Abnormal sleep and sleepiness in Parkinson's disease. Curr Opin Neurol 2008; 21: 472-7.

Matuja WB, Aris EA. Motor and non-motor features of Parkinson's disease. East Afr Med J 2008; 85: 3-9.

Rahman S, Griffin HJ, Quinn NP, Jahanshahi M. Quality of life in Parkinson's disease: the relative importance of the symptoms. Mov Disord 2008; 23: 1428-34.

Gallagher DA, Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease. CNS Drugs 2008; 22: 563-86.

Dowding CH, Shenton CL, Salek SS. A review of the health-related quality of life and economic impact of Parkinson's disease. Drugs Aging 2006; 23: 693-721.

Damiano AM, McGrath MM, Willian MK, Snyder CF, LeWitt PA, Reyes PF, et al. Evaluation of a measurement strategy for Parkinson’s disease: assessing patient healthrelated quality of life. Qual Life Res 2000; 9: 87-100.

Scheife RT, Schumock GT, Burstein A, Gottwald MD, Luer MS. Impact of Parkinson’s disease and its pharmacologic treatment on quality of life and economic outcomes. Am J Health Syst Pharm 2000; 57: 953-62.

Chrischillies EA, Rubenstein LM, Voelker MD, Wallace RB, Rodnitzky RL. The health burdens of Parkinson’s disease. Mov Disord 1998; 13: 406-13.

Dodel RC, Singer M, Köhne-Volland R, Szucs T, Rathay B, Scholz E, et al. The economic impact of Parkinson’s disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics 1998; 14: 299-312.

LeWitt PA. The challenge of managing mild Parkinson’s disease. Pharmacotherapy 2000; 20: 2S-7S.

Tison F. Diagnostic criteria of parkinsonian syndromes. Rev Neurol (Paris) 2003; 159: S19-23.

Dohm CP, Pilgram SM, Liman J, Bähr M, Mohr A, Kermer P. Differential diagnosis of Parkinson's syndromesan overview. Dtsch Med Wochenschr 2009; 134: 892-6.

Duchesne S, Rolland Y, Vérin M. Automated computer differential classification in Parkinsonian Syndromes via pattern analysis on MRI. Acad Radiol 2009; 16: 61-70.

Rango M, Arighi A, Biondetti P, Barberis B, Bonifati C, Blandini F, et al. Magnetic resonance spectroscopy in Parkinson's disease and parkinsonian syndromes. Funct Neurol 2007; 22: 75-9.

Weiner WJ. A differential diagnosis of Parkinsonism. Rev Neurol Dis 2005; 2: 124-31.

Takáts A. Diagnostic criteria and differential diagnosis of Parkinson disease. Ideggyogy Sz 2003; 56: 144-54.

Camicioli R. Identification of Parkinsonism and Parkinson's disease. Drugs Today (Barc) 2002; 38: 677-86.

Poewe W. Treatments for Parkinson’s disease-past achievements and current clinical needs. Neurology 2009; 72: 65-73.

Fahn S. How do you treat motor complications in Parkinson’s disease: Medicine, surgery, or both? Ann Neurol 2008; 64: 56-64.

Randall MD, Neil KE. Disease Management, 2nd ed., Pharmaceutical Press 2009; Chap. 28.

Stern MB. Dopamine agonists modify the course of Parkinson’s disease. Arch Neurol 2004; 61: 1969-71.

Weiner WJ. Initial treatment of Parkinson’s disease: levodopa or dopamine agonists. Arch Neurol 2004; 61: 1966-9.

Jankovic J. Motor fluctuations and dyskinesias in Parkinson’s disease: Clinical manifestations. Mov Disord 2005; 20: 11-6.

Jankovic J. Therapeutic strategies in Parkinson’s disease. In: Jankovic J, Tolosa E, Eds. Parkinson’s disease and Movement Disorders, 4th ed. Lippincott Williams and Wilkins: Philadelphia 2002; pp. 116-51.

Bhidayasiri R, Ling H. Treatment of Parkinson’s disease in Thailand: review of the literature and practical recommendations. J Med Assoc Thai 2009; 92: 142-54.

Jankovic J. Parkison’s disease therapy: Tailoring choices for early and late disease, young and old patients. Clin Neuropharmacol 2000; 23: 252-61.

Lang AE. When and how should treatment be started in Parkinson’s disease? Neurol 2009; 72: S39-43.

Brooks DJ. Dopamine agonists: their role in the treatment of Parkinson’s disease. J Neurol Neurosurg Psychiatry 2000; 68: 685-9.

Schrag A. Entacapone in the treatment of Parkinson’s disease. Lancet Neurol 2005; 4: 366-70.

Assal F, Spahr L, Hadengue A, Rubbici-Brandt L, Burkhard PR. Tolcapone and fulminant hepatitis. Lancet 1998; 352: 958.

Olanow CW. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol 2000; 57: 263-7.

Ellison RH. Dear health professional letter regarding appropriate use of Tasmar. Nutley, NJ: Roche Laboratories Inc 1998.

Lees AJ, Ratziu V, Tolosa E, Oertel WH. Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson’s disease. J Neurol Neurosurg Psychiatry 2007; 78: 944-8.

Ruottinen HM, Rinne UK. COMT inhibition in the treatment of Parkinson’s disease. J Neurol 1998; 245: 25-34.

Grandas F, Heernandez B; PRACTICOMT Study Group. Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson’s disease patients: the effects of an elderly therapeutic intervention. Eur J Neurol 2007; 14: 282-9.

Modolo J, Beuter A. Linking brain dynamics, neural mechnamics, and deep brain stimulation in Parkinson’s disease: An integrated perspective. Med Eng Phys 2009; 31: 615-23.

Bäumer T, Hidding U, Hamel W, Buhmann C, Moll CK, Gerloff C, et al. Effects of DBS, premotor rTMS, and levodopa on motor function and silent period in advanced Parkinson’s disease. Mov Disord 2009; 24: 672-6.

Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson’s disease. Arch Neurol 1999; 56: 33-9.

Sharma N. Parkinson’s Disease. Greenwood Press 2008.

Chou KL, Baltuch GH, Stern MB. Overview. In: Baltuch GH, Stern MB Eds., Surgical Management of Movement Disorders. Taylor & Francis: Boca Raton, FL 2005; Chap. 1.

Bergman H, Wichmann T, DeLong MR. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990; 249: 1436-8.

Gill SS, Heywood P. Bilateral dorsolateral subthalamotomy for advanced Parkinson’s disease. Lancet 1997; 350: 1224.

Alvarez L, Macias R, Guridi J, Lopez G, Alvarez E, Maragoto C, et al. Dorsal subthalamotomy for Parkinson’s disease. Mov Disord 2001; 16: 72-8.

Patel NK, Heywood P, O’Sullivan K, McCarter R, Love S, Gill SS. Unilateral subthalamotomy in the treatment of Parkinson’s disease. Brain 2003; 126: 1136-45.

Su PC, Tseng HM, Liu HM, Yen RF, Liou HH. Treatment of advanced Parkinson’s disease by subthalamotomy: oneyear results. Mov Disord 2003; 18: 531-8.

Ghika J, Ghika-Schmid F, Fankhauser H, Assal G, Vingerhoets F, Albanese A, et al. Bilateral contemporaneous posteroventral pallidotomy for the treatment of Parkinson’s disease: neuropsychological and neurological side effects. Report of four cases and review of the literature. J Neurosurg 1999; 91: 313-21.

Lang AE, Duff J, Saint-Cyr JA, Trepanier L, Gross RE, Lombardi W, et al. Posteroventral medial pallidotomy in Parkinson’s disease. J Neurol 1999; 246: 1128-41.

Favre J, Burchiel KJ, Taha JM, Hammerstad J. Outcome of unilateral and bilateral pallidotomy for Parkinson’s disease: patient assessment. Neurosurgery 2000; 46: 344-55.

De Bie RM, Schuurman PR, Esselink RA, Bosch DA, Speelman JD. Bilateral pallidotomy in Parkinson’s disease: a retrospective study. Mov Disord 2002; 17: 533-8.

Lozano AM, Lang AE, Galvez-Jimenez N, Miyasaki J, Duff J, Hutchinson WD, et al. Effect of GPi pallidotomy on motor function in Parkinson’s disease. Lancet 1995; 346: 1383-7.

Laitinen LV, Bergenheim AT, Hariz MI. Leksell’s posteroventral pallidotomy in the treatment of Parkinson’s disease. J Neurosurg 1992; 76: 53-61.

Baron MS, Vitek JL, Bakay RA, Green J, Kaneoke Y, Hashimoto T, et al. Treatment of advanced Parkinson’s disease by posterior GPi pallidotomy: 1-year results of a pilot study. Ann Neurol 1996; 40: 355-66.

Kishore A, Turnbull IM, Snow BJ, de la Fuente- Fernandez R, Schulzer M, Mak E, et al. Efficacy, stability and predictors of outcome of pallidotomy for Parkinson’s disease. Six-month follow-up with additional 1-year observations. Brain 1997; 120: 729-37.

Krauss JK, Desaloms JM, Lai EC, King DE, Jankovic J, Grossman RG. Microelectrode-guided posteroventral pallidotomy for treatment of Parkinson’s disease: postoperative magnetic resonance imaging analysis. J Neurosurg 1997; 87: 358-67.

Uitti RJ, Wharen RE Jr, Turk MF, Lucas JA, Finton MJ, Graff-Radford NR, et al. Unilateral pallidotomy for Parkinson’s disease: comparison of outcome in younger versus elderly patients. Neurology 1997; 49: 1072-7.

Fine J, Duff J, Chen R, Chir B, Hutchison W, Lozano AM, et al. Longterm follow-up of unilateral pallidotomy in advanced Parkinson’s disease. N Engl J Med 2000; 342: 1708-14.

Baron MS, Vitek JL, Bakay RA, Green J, McDonald WM, Cole SA, et al. Treatment of advanced Parkinson’s disease by unilateral posterior GPi pallidotomy: 4-year results of a pilot study. Mov Disord 2000; 15: 230-7.

Pal PK, Samii A, Kishore A, Schulzer M, Mak E, Yardley S, et al. Long term outcome of unilateral pallidotomy: follow up of 15 patients for 3 years. J Neurol Neurosurg Psychiatry 2000; 69: 337-44.

Ohye C, Hirai T, Miyazaki M, Shibazaki T, Nakajima H. Vim thalamotomy for the treatment of various kinds of tremor. Appl Neurophysiol 1982; 45: 275-80.

Nagaseki Y, Shibazaki T, Hirai T, Kawashima Y, Hirato M, Wada H, et al. Long-term follow-up results of selective VIMthalamotomy. J Neurosurg 1986; 65: 296-302.

Mohadjer M, Goerke H, Milios E, Etou A, Mundinger F. Long-term results of stereotaxy in the treatment of essential tremor. Stereotact Funct Neurosurg 1990; 54-55: 125-9.

Goldman MS, Ahlskog JE, Kelly PJ. The symptomatic and functional outcome of stereotactic thalamotomy for medically intractable essential tremor. J Neurosurg 1992; 76: 924-8.

Jankovic J, Cardoso F, Grossman RG, Hamilton WJ. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery 1995; 37: 680-7.

Tasker RR. Deep brain stimulation is preferable to thalamotomy for tremor suppression. Surg Neurol 1998; 49: 145-54.

Schuurman PR, Bosch DA, Bossuyt PM, Bonsel GJ, van Someren EJ, de Bie RM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med 2000; 342: 461-8.

Bittar RG, Hyam J, Nandi D, Wang S, Liu X, Joint C, et al. Thalamotomy versus thalamic stimulation for multiple sclerosis tremor. J Clin Neurosci 2005; 12: 638-42.

Kim MJ, Jeon SR, Yoo HW, Kim GH, Lee MC, Chung SJ. Effect of thalamotomy on focal hand dystonia in a family with DYT1 mutation. Mov Disord 2008; 23: 2251-5.

Schuurman PR, Bosch DA, Merkus MP, Speelman JD. Long-term follow-up of thalamic stimulation versus thalamotomy for tremor suppression. Mov Disord 2008; 23: 1146-53.

Nijhawan SR, Banks SJ, Aziz TZ, Panourias I, Gregory R, Yianni J, et al. Changes in cognition and health-related quality of life with unilateral thalamotomy for Parkinsonian tremor. J Clin Neurosci 2009; 16: 44-50.

Moro E, Allert N, Eleopra R, Houeto JL, Phan TM, Stoevelaar H, et al. A decision tool to support appropriate referral for deep brain stimulation in Parkinson's disease. J Neurol 2009; 256: 83-8.

Volkmann J. Deep brain stimulation for the treatment of Parkinson's disease. J Clin Neurophysiol 2004; 21: 6-17.

Limousin P, Martinez-Torres I. Deep brain stimulation for Parkinson's disease. Neurotherapeutics 2008; 5: 309-19.

Papapetropoulos S, Jagid JR, Sengun C, Singer C, Gallo BV. Objective monitoring of tremor and bradykinesia during DBS surgery for Parkinson disease. Neurology 2008; 70: 1244-9.

Earhart GM, Hong M, Tabbal SD, Perlmutter JS. Effects of thalamic stimulation frequency on intention and postural tremor. Exp Neurol 2007; 208: 257-63.

Takagi M. Safety and neuroethical consideration of deep brain stimulation as a psychiatric treatment. Brain Nerve 2009; 61: 33-40.

Lyons KE, Pahwa R. Deep brain stimulation and tremor. Neurotherapeutics 2008; 5: 331-8.

Schuurman PR, Bosch DA, Bossuyt PM, Bonsel GJ, van Someren EJ, de Bie RM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med 2000; 342: 461-8.

Pahwa R, Lyons KE, Wilkinson SB, Tröster AI, Overman J, Kieltyka J, et al. Comparison of thalamotomy to deep brain stimulation of the thalamus in essential tremor. Mov Disord 2001; 16: 140-3.

Dowling J. Deep brain stimulation: current and emerging indications. Mo Med 2008; 105: 424-8.

Yu H, Neimat JS. The treatment of movement disorders by deep brain stimulation. Neurotherapeutics 2008; 5: 26-36.

Bejjani BP, Gervais D, Arnulf I, Papadopoulos S, Demeret S, Bonnet AM, et al. Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation. J Neurol Neurosurg Psychiatry 2000; 68: 595-600.

Timmermann L, Braun M, Groiss S, Wojtecki L, Ostrowski S, Krause H, et al. Differential effects of levodopa and subthalamic nucleus deep brain stimulation on bradykinesia in Parkinson's disease. Mov Disord 2008; 23: 218-27.

Baltuch GH, Stern MB. Deep Brain Stimulation for Parkinson's Disease. Informa Healthcare: USA, Inc., 2007.

Diamond A, Jankovic J. The effect of deep brain stimulation on quality of life in movement disorders. J Neurol Neurosurg Psychiatry 2005; 76: 1188-93.

Pahwa R, Lyons KE, Wilkinson SB, Simpson RK Jr, Ondo WG, Tarsy D, et al. Long-term evaluation of deep brain stimulation of the thalamus. J Neurosurg 2006; 104: 506- 512.

Ellis TM, Foote KD, Fernandez HH, Sudhyadhom A, Rodriguez RL, Zeilman P, et al. Reoperation for suboptimal outcomes after deep brain stimulation surgery. Neurosurgery 2008; 63: 754-61.

Guridi J, Rodriguez-Oroz MC, Arbizu J, Alegre M, Prieto E, Landecho I, et al. Successful thalamic deep brain stimulation for orthostatic tremor. Mov Disord 2008; 23: 1808-11.

Breit S, Wächter T, Schöls L, Gasser T, Nägele T, Freudenstein D, et al. Effective thalamic deep brain stimulation for neuropathic tremor in a patient with severe demyelinating neuropathy. J Neurol Neurosurg Psychiatry 2009; 80: 235-6.

Papapetropoulos S, Gallo BV, Guevara A, Singer C, Mitsi G, Lyssikatos C, et al. Objective tremor registration during DBS surgery for essential tremor. Clin Neurol Neurosurg 2009; 111: 376-9.

Blomstedt P, Fytagoridis A, Tisch S. Deep brain stimulation of the posterior subthalamic area in the treatment of tremor. Acta Neurochir (Wien) 2009; 151: 31- 6.

Kim HJ, Paek SH, Kim JY, Lee JY, Lim YH, Kim DG, et al. Two-year follow-up on the effect of unilateral subthalamic deep brain stimulation in highly asymmetric Parkinson's disease. Mov Disord 2009; 24: 329-35.

Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ Jr, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. JAMA 2009; 301: 63- 73.

Lopiano L, Rizzone M, Bergamasco B, Tavella A, Torre E, Perozzo P, et al. Deep brain stimulation of the subthalamic nucleus in PD: an analysis of the exclusion causes. J Neurol Sci 2002; 195: 167-70.

Charles PD, Van Blercom N, Krack P, Lee SL, Xie J, Besson G, et al. Predictors of effective bilateral subthalamic nucleus stimulation for PD. Neurology 2002; 59: 932-4.

Welter ML, Houeto JL, Tezenas du Montcel S, Mesnage V, Bonnet AM, Pillon B, et al. Clinical predictive factors of subthalamic stimulation in Parkinson’s disease. Brain 2002; 125: 575-83.

Sestini S, Pupi A, Ammannati F, Ramat S, Sorbi S, Sciagrà R, et al. Predictive potential of pre-operative functional neuroimaging in patients treated with subthalamic stimulation. Eur J Nucl Med Mol Imaging 2010; 37: 12-22.

Umemura A, Jaggi JL, Hurtig HI, Siderowf AD, Colcher A, Stern MB, et al. Deep brain stimulation for movement disorders: morbidity and mortality in 109 patients. J Neurosurg 2003; 98: 779-84.

Bojanic S, Sethi H, Hyam J, Yianni J, Nandi D, Joint C, et al. Externalising deep brain electrodes: an increased risk of infection? J Clin Neurosci 2004; 11: 732-4.

Temel Y, Ackermans L, Celik H, Spincemaille GH, van der Linden C, Walenkamp GH, et al. Management of hardware infections following deep brain stimulation. Acta Neurochir (Wien) 2004; 146: 355-61.

Paluzzi A, Belli A, Bain P, Liu X, Aziz TM. Operative and hardware complications of deep brain stimulation for movement disorders. Br J Neurosurg 2006; 20: 290-5.

Zabek M, Sobstyl M. Deep brain stimulation in the management of Parkinson's disease. Neurol Neurochir Pol 2006; 40: 203-11.

Appleby BS, Duggan PS, Regenberg A, Rabins PV. Psychiatric and neuropsychiatric adverse events associated with deep brain stimulation: A meta-analysis of ten years' experience. Mov Disord 2007; 22: 1722-8.

Chou YC, Lin SZ, Hsieh WA, Lin SH, Lee CC, Hsin YL, et al. Surgical and hardware complications in subthalamic nucleus deep brain stimulation. J Clin Neurosci 2007; 14: 643-9.

Seijo FJ, Alvarez-Vega MA, Gutierrez JC, Fdez-Glez F, Lozano B. Complications in subthalamic nucleus stimulation surgery for treatment of Parkinson's disease. Review of 272 procedures. Acta Neurochir (Wien) 2007; 149: 867-76.

Voges J, Hilker R, Bötzel K, Kiening KL, Kloss M, Kupsch A, et al. Thirty days complication rate following surgery performed for deep-brain-stimulation. Mov Disord 2007; 22: 1486-9.

Vesper J, Haak S, Ostertag C, Nikkhah G. Subthalamic nucleus deep brain stimulation in elderly patients--analysis of outcome and complications. BMC Neurol 2007; 7: 7.

Sillay KA, Larson PS, Starr PA. Deep brain stimulator hardware-related infections: incidence and management in a large series. Neurosurgery 2008; 62: 360-7.

Witt K, Daniels C, Reiff J, Krack P, Volkmann J, Pinsker MO, et al. Neuropsychological and psychiatric changes after deep brain stimulation for Parkinson's disease: a randomised, multicentre study. Lancet Neurol 2008; 7: 605- 14.

Bhatia S, Oh M, Whiting T, Quigley M, Whiting D. Surgical complications of deep brain stimulation. A longitudinal single surgeon, single institution study. Stereotact Funct Neurosurg 2008; 86: 367-72.

Lanotte M, Verna G, Panciani PP, Taveggia A, Zibetti M, Lopiano L, et al. Management of skin erosion following deep brain stimulation. Neurosurg Rev 2009; 32: 111-5.

Uitti RJ. Surgical treatments for Parkinson’s disease. Can Fam Physician 2000; 46: 368-73.

Okun MS, Tagliati M, Pourfar M, Fernandez HH, Rodriguez RL, Alterman RL, et al. Management of referred deep brain stimulation failures: a retrospective analysis from 2 movement disorders centers. Arch Neurol 2005; 62: 1250-5.

Henderson JM, Tkach J, Phillips M, Baker K, Shellock FG, Rezai AR. Permanent neurological deficit related to magnetic resonance imaging in a patient with implanted deep brain stimulation electrodes for Parkinson’s disease: a case report. Neurosurgery 2005; 57: 1063.

Kainz W, Alesch F, Chan DD. Electromagnetic interference of GSM mobile phones with the implantable deep brain stimulator, ITREL-III. Biomed Eng Online 2003; 2: 11.





Add comment 





Home  Editorial Board  Search  Current Issue  Archive Issues  Announcements  Aims & Scope  About the Journal  How to Submit  Contact Us
Find out how to become a part of the HMJ  |   CLICK HERE >>
© Copyright 2012 - 2013 HMJ - HAMDAN Medical Journal. All Rights Reserved         Website Developed By Cedar Solutions INDIA